# Bcl-6 (3-484): sc-4105



The Power to Question

## **BACKGROUND**

Relatively little is known regarding the molecular pathogenesis of diffuse large-cell lymphoma (DLCL), the most frequent and most lethal human lymphoma. DLCL accounts for approximately 40% of all non-Hodgkin's lymphomas. Chromosomal trans-locations involving reciprocal recombination between band 3q27 and several other chromosomal sites are involved in 8 to 12% of non-Hodgkin's lymphomas; a breakpoint cluster region at 3q27 has been identified and designated Bcl-6. This gene has been shown to encode a protein of 706 amino acids with a predicted molecular weight of 79 kDa. The Bcl-6 protein has homology with zinc finger transcription factors and was found to be rearranged in 13 of 39 DLCL samples.

# **REFERENCES**

- 1. Ree, H.J., et al. 2003. Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. Hum Pathol 34: 610-616.
- 2. Logarajah, S., et al. 2003. Bcl-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene 22: 5572-5578.
- 3. Bos, R., et al. 2003. Protein expression of B-cell lymphoma gene 6 (Bcl-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1a (HIF-1a). Oncogene 22: 8948-8951.
- 4 Pasqualucci, L., et al. 2003. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk. Lymphoma 44 Suppl. 3: S5-S12.
- 5. Kurosu, K., et al. 2004. Bcl-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia. J. Immunol. 172: 7116-7122.
- Tunyaplin, C., et al. 2004. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J. Immunol. 173: 1158-1165.
- 7. Ozaki, K., et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173: 5361-5371.
- 8. Li, Z., et al. 2005. Bcl-6 negatively regulates expression of the NFkB1 p105/p50 subunit. J. Immunol. 174: 205-214.
- 9. Harris, M.B., et al. 2005. Repression of an interleukin-4-responsive promoter requires cooperative Bcl-6 function. J. Biol. Chem .280: 13114-13121.
- Scheeren, F.A., et al. 2005. Stat5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat. Immunol. 6: 303-313.

## **SOURCE**

Bcl-6 (3-484) is expressed in E. coli as an 80 kDa tagged fusion protein corresponding to amino acids 3-484 mapping at the amino terminus of Bcl-6 of human origin.

#### **STORAGE**

Store at -20° C; stable for one year from the date of shipment.

#### **PRODUCT**

Bcl-6 (3-484) is purified from bacterial lysates (> 98%) by glutathione agarose affinity chromatography; supplied as 50  $\mu$ g in 50  $\mu$ l of protein in 1X PBS, 50% glycerol, 5 mM DTT

## **APPLICATIONS**

Bcl-6 (3-484) is suitable as a Western blotting control for sc-7388, sc-56625, sc-70414 and sc-130916.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com